Clinical trials: Withdrawal
Thyroid Cancer
Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer
To evaluate quality of life in patients after 10 days pause of thyroid medication (Liothyronine) compared to treatment with recombinant TSH (Thyrogen) before radioiodine uptake and treatment in a double-blinded, randomised…
- Trial name
- NCT00604318
- Testing
- rhTSH
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Copenhagen University Hospital at Herlev
Dementia, Alzheimer Disease
Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects
Capturing the earliest stages of Dementia especially Alzheimer's Disease (AD) is a great challenge. Until now the NINCDS-ADRDA and the DSM criteria for AD were largely used as diagnostic standards in research.
- Trial name
- AMIMAGE (NCT00951197)
- Testing
- Neuroimaging
- Where
- France
- Volunteers
- 318 people
- Sponsor
- University Hospital, Bordeaux
Knee Osteoarthritis
Neurofeedback for Pain Sensitization in Knee Osteoarthritis
The goal of this clinical trial is to learn whether a training method called neurofeedback is safe and practical to use in people with knee osteoarthritis (knee OA).
- Trial name
- NCT07832682
- Testing
- FWR Down-Conditioning Neurofeedback
- Volunteers
- 50 people
- Sponsor
- Northeastern University
Cognitive Impact of Antiepileptic Drugs
Cognitive Impact of Benzodiazepin Withdrawn After Curative Epilepsy Surgery in Children With Focal Epilepsy
Epilepsy is a frequent group of diseases, affecting 1% of the general population with a higher incidence in children. Anti-epileptic drugs are used as part of the drug treatment.
- Trial name
- COGNIBENZO (NCT03803046)
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Substance Withdrawal Syndrome, Opiate Addiction
Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
The purpose of this study is to evaluate the relative exposures of lofexidine and its major metabolites in subjects seeking buprenorphine dose reduction.
- Conditions
- Substance Withdrawal Syndrome, Opiate Addiction, Opiate Dependence
- Trial name
- NCT02801357
- Testing
- lofexidine administration in subjects seeking buprenorphine dose reduction
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Systemic Lupus Erythematosus
Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
Hypothesis: A reason for repeated disappointing outcomes of clinical trials testing targeted immune biologics for lupus may be the heterogeneity of the disease, exacerbated by the variable effects on immune homeostasis of the…
- Trial name
- BOLD (NCT00987831)
- Testing
- Group B SLE one blood donation, Blood drawing only Group C, Group A SLE prospective study
- Where
- 2 sites in United States
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Oklahoma Medical Research Foundation
COVID-19, ARDS
Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19
The analgesic and sedation requirements in critically ill patients with COVID-19 have yet to be described. There are various factors that are likely affecting the agents being utilized for analgesia and sedation in these patients…
- Conditions
- COVID-19, ARDS, Withdrawal Syndrome, Iatrogenic Disease
- Trial name
- NCT05336656
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- Wilkes University
Systemic Lupus Erythematosus, Glucocorticoids
Glucocorticoids Withdrawal in Early Systemic Lupus Erythematosus
This is a 36 months, randomized, double-blind, placebo-controlled, parallel-groups, equivalence multicenter trial in patients with inactive Systemic Lupus Erythematosus to evaluate if low disease activity can be sustained with…
- Conditions
- Systemic Lupus Erythematosus, Glucocorticoids, Therapy Withdrawal
- Trial name
- NCT03804723
- Testing
- oral Prednisone 5mg
- Volunteers
- 321 people
- Sponsor
- University of Pisa
Hyponatremia
Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia
The purpose of this trial was to demonstrate that tolvaptan effectively and safely increases and maintains serum sodium concentrations in children and adolescent participants with euvolemic or hypervolemic hyponatremia.
- Trial name
- NCT02012959
- Testing
- Tolvaptan
- Where
- 7 sites in United States, Italy and 1 more
- Volunteers
- 9 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alcoholism, Substance-Related Disorders
Intranasal Oxytocin Effects in Alcohol Withdrawal and Dependence; Follow-up Study
This study is an assessment of the long-term effect of oxytocin nasal spray on alcohol withdrawal and dependence in adults admitted for detoxification of alcohol after 60 days and 1 year.
- Trial name
- NCT03339024
- Testing
- intranasal oxytocin spray, intranasal spray without oxytocin
- Where
- Norway
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Cognitive Function, Mood
Cognitive and Cerebral Blood Flow Effects of 2-week Caffeine Abstinence or Maintenance
The purpose of this study is to determine the effects of 2 weeks caffeine abstinence as compared to 2 weeks caffeine maintenance (300mg per day)on cognition and mood.
- Conditions
- Cognitive Function, Mood, Cerebral Haemodynamics, Caffeine Withdrawal
- Trial name
- NCT01376882
- Testing
- Caffeine
- Where
- United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Northumbria University
Chronic Kidney Disease, Hyperphosphatemia
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a…
- Trial name
- NCT00416520
- Testing
- MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®), Another phosphate binder (Sevelamer)
- Where
- 68 sites in Australia, Austria and 9 more
- Volunteers
- 336 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
The study is a prospective, randomized, 52-week double-blind, placebo-controlled, multicenter trial in subjects with Type 1 diabetes (T1D) followed by a 2-year safety follow-up.
- Trial name
- SUNRISE (NCT03895437)
- Testing
- TOL-3021
- Where
- 23 sites in United States
- Volunteers
- 78 people
- Sponsor
- Tolerion, Inc.
Chronic Pain, Analgesics, Opioid
Tapering From Long-term Opioid Therapy in Chronic Pain Population. Randomized Controlled Trial With 12 Months Follow up
This randomized controlled study compares tapering of long-term opioid therapy in a population with chronic non-cancer pain with control group constituted of waiting list.
- Conditions
- Chronic Pain, Analgesics, Opioid, Opioid Withdrawal, Opioid Use
- Trial name
- TOPIO (NCT03485430)
- Testing
- Tapering
- Where
- 3 sites in Sweden
- Volunteers
- 140 people
- Sponsor
- Lund University Hospital
Neuropsychiatric Syndrome, Autism Spectrum Disorder
Nature and Animal-assisted Activities
Neuropsychiatric impairments in young adults are common and can involve social withdrawal, and difficulties in receiving support from healthcare and municipal social care services.
- Trial name
- NCT06431126
- Testing
- Nature and animal-assisted activities
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Kronoberg County Council
Cystic Fibrosis
A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)
This was a multicenter, randomized, double-blind, placebo-controlled study of patients with severe, though stable, cystic fibrosis (CF) whose routine treatment included Pulmozyme.
- Trial name
- NCT00434278
- Testing
- Dornase alfa
- Where
- 40 sites in United States
- Volunteers
- 27 people
- Sponsor
- Genentech, Inc.
Drug; Withdrawal Symptoms, Neonatal, Withdrawal
Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study
Summary: There have been two published RCTs showing efficacy of buprenorphine treatment for NAS. However these trials excluded an estimated 22-47% of infants requiring pharmacologic treatment; those infants born to mothers with…
- Conditions
- Drug; Withdrawal Symptoms, Neonatal, Withdrawal, Fetus and Newborn Affected by Other Maternal Medication
- Trial name
- NCT02249026
- Testing
- BZDs + opiate exposure treated with BPN, Opiates exposure treated with BPN
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Gauda, Estelle B., M.D.
Alcohol Withdrawal, Alcohol Dependence
Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal
This study will explore the effectiveness and tolerability of Cannabidiol (CBD) in the treatment of alcohol withdrawal symptoms in an inpatient setting, in a double-blind randomised placebo-controlled trial.
- Trial name
- NCT04205682
- Testing
- Cannabidiol
- Where
- 2 sites in Australia
- Volunteers
- 52 people
- Sponsor
- South West Sydney Local Health District
Chronic Kidney Diseases
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage…
- Trial name
- Clarion-CKD (NCT04968184)
- Testing
- KBP-5074
- Where
- 215 sites in United States, Australia and 20 more
- Volunteers
- 666 people
- Sponsor
- Novo Nordisk A/S
Binge-Eating Disorder
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder
This is a Phase 3, multi-center, open-label and randomized withdrawal study to evaluate the long-term safety and efficacy of solriamfetol in the treatment of binge eating disorder (BED) in adults.
- Trial name
- NCT06878976
- Testing
- Solriamfetol
- Where
- 33 sites in United States
- Volunteers
- 236 people
- Sponsor
- Axsome Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.